Action 460 SIHUAN PHARMACEUTICAL HOLDINGS GROUP LTD.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Autres langues Sihuan Pharmaceutical Holdings Group Ltd.

Actions

460

BMG8162K1137

Marché Fermé - Hong Kong S.E.
Autres places de cotation
 10:09:00 03/05/2024 		Varia. 5j. Varia. 1 janv.
0,61 HKD -3,17% Graphique intraday de Sihuan Pharmaceutical Holdings Group Ltd. +8,93% -6,15%
02/05 La NDA du médicament contre le cancer du poumon de Sihuan Pharmaceutical Unit est acceptée par la NMPA, les actions grimpent de plus de 10%. MT
25/04 Une unité de Sihuan Pharma remporte un appel d'offres pour la fourniture de produits d'insuline au gouvernement chinois MT

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
Sihuan Pharmaceutical Unit's Lung Cancer Drug NDA Accepted by NMPA, Stocks Shoot Over 10%
Sihuan Pharma Unit Wins Bid to Supply Insulin Products to Chinese Government
Sihuan Pharmaceutical Narrows 2023 Loss on Absence of Asset, Investment Impairments
Sihuan Pharmaceutical Holdings Group Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
Sihuan Pharmaceutical's RF Device Wins Registration Approval in China
Sihuan Pharmaceutical Holdings Unit Forms Consortium for Ji Yao Restructuring
China Approves Drug Registration for Sihuan Pharmaceutical Unit's Type 2 Diabetes Drug
Sihuan Pharmaceutical Holdings Group Ltd. Receives Registration Approval from National Medical Products Administration for Proline Janagliflozin Tablets
China Includes Four Injectables by Sihuan Pharma Associate in Drug Reimbursement List; Shares Rise 3%
China Grants Registration Approval to Sihuan Pharmaceutical's Insulin Products
Sihuan Pharmaceutical Holdings Group Ltd. Obtains Drug Registration Approval from the National Medical Products Administration of the People's Republic of China for the Treatment of Diabetes
China's Medical Products Administrator Approves Sihuan Pharma Unit's Diabetes Drug
National Medical Products Administration Approves IND Application of Insulin Degludec and Liraglutide Injection, Developed by Huisheng Biopharmaceutical
China Accepts New Drug Application of Sihuan Pharmaceutical Subsidiary's Breast Cancer Treatment
Sihuan Pharmaceutical Was Selected As One Of The First Echelon Of Enterprises In The list of China's Top 100 Pharmaceutical Innovative Enterprises in 2023
China Accepts New Drug Application for Sihuan Pharmaceutical Unit's Breast Cancer Tablets
Sihuan Pharmaceutical Swings to H1 Loss
Sihuan Pharmaceutical Holdings Group Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023
Sihuan Pharmaceutical's Revenue to Drop 30% in H1
Sihuan Pharmaceutical Holdings Group Ltd. Provides Unaudited Consolidated Guidance for the Six Months Ended 30 June 2023
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action 460
  4. Actualités Sihuan Pharmaceutical Holdings Group Ltd.
  5. Autres langues